Table 4.
Conditions for which respondents considered that a point-of-care test would help them to monitor or manage patients’ conditions: top 20 in the UK
| Monitoring | ||
|---|---|---|
| Number of respondentsRespondents reporting conditionsNumber of conditions recorded | 110910423285 | |
| Condition | Percentage of total recorded conditions (n) | Percentage of respondents recording condition |
| International normalized ratio/anticoagulation | 16.7 (547) | 49.3 |
| Diabetes (not otherwise specified) | 16.0 (527) | 47.5 |
| Acute and chronic renal impairment/failure | 7.0 (230) | 20.7 |
| Chronic obstructive pulmonary disease/asthma | 6.8 (223) | 20.1 |
| Lipid disorder | 4.7 (154) | 13.9 |
| Hyper/hypothyroidism | 3.8 (126) | 11.4 |
| Anaemia | 3.7 (121) | 10.9 |
| Musculoskeletal inflammation (including rheumatic disease) | 3.2 (105) | 9.5 |
| Pulmonary embolism/deep vein thrombosis | 3.2 (104) | 9.4 |
| Cancer | 3.0 (100) | 9.0 |
| Heart failure | 2.8 (93) | 8.4 |
| Urinary tract infection | 2.5 (83) | 7.5 |
| Diabetes insulin dependent/diabetes, non-insulin dependent (HbA1c testing) | 2.2 (73) | 6.6 |
| Acute cardiac disease | 1.5 (49) | 4.4 |
| Cardiovascular disease, other | 1.5 (49) | 4.4 |
| Hypertension | 1.2 (41) | 3.7 |
| Diabetes (glucose) | 1.1 (37) | 3.3 |
| Acute infection (bacterial versus viral not otherwise specified) | 1.0 (34) | 3.1 |
| Chest infection/cough/lower respiratory tract infection | 1.0 (32) | 2.9 |
| Rheumatoid arthritis/osteoarthritis drug monitoring | 0.9 (29) | 2.7 |